Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

AIM: This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL), clinical outcomes and healthcare utilization in US patients with castration-resistant prostate cancer (CRPC). PATIENTS & METHODS: Treatment Registry for Outcomes in CRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Penson, David F, Lin, Daniel W, Karsh, Lawrence, Quinn, David I, Shevrin, Daniel H, Shore, Neal, Symanowski, James T, Brown, Bruce, Forer, David, Wong, Elaine K, Flanders, Scott C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116579/
https://www.ncbi.nlm.nih.gov/pubmed/27528114
http://dx.doi.org/10.2217/fon-2016-0298
Descripción
Sumario:AIM: This study seeks to improve the understanding of treatment patterns and associated health-related quality of life (HRQoL), clinical outcomes and healthcare utilization in US patients with castration-resistant prostate cancer (CRPC). PATIENTS & METHODS: Treatment Registry for Outcomes in CRPC Patients (TRUMPET) is a US-based, prospective, observational multicenter registry (NCT02380274) involving patients with CRPC and their caregivers. Patients initiating their first active treatment course will be enrolled from urology and medical oncology practices, with data captured up to 4 years. RESULTS: Information on prescribing patterns, HRQoL, clinical outcomes and healthcare utilization will be collected. CONCLUSION: TRUMPET will enable scientific understanding of disease management in terms of HRQoL, clinical outcomes and healthcare utilization in clinical practice for patients with CRPC.

Ejemplares similares